GSK to pay Chroma up to $1 billion in inflammatory disease deal
23 June 2009
Simon Varcoe
GlaxoSmithKline could pay the UK-based private drug discovery company
Chroma Therapeutics more than $1 billion to develop macrophage-targeted drugs in an agreement signed with GSK's Centre of Excellence for External Drug Discovery.
Using its esterase-sensitive motif (ESM) technology, Chroma will...
Please Login to read the full article.
23 June 2009
Simon Varcoe
Using its esterase-sensitive motif (ESM) technology, Chroma will...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Xoma to use acquired Servier hypertension drug to establish a US commercial operation
- Chroma/CTI plan tosedostat PhIII to avoid AML trap that caught Vion, J&J and Genzyme
- Innate pockets $35 million from BMS for Phase I anticancer antibody
- Merck Serono taps Threshold for Ph III cancer drug
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
